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Why do we need Pharmaceutical Care Pathways? 
Laura Rooney 
 
Developing a sustainable pharmaceutical care pathway is EHFRPLQJYHU\LPSRUWDQWLQWRGD\¶V
healthcare system in Scotland. If the NHS is to ensure that communities are sharing the workload with 
the primary and secondary care services, the pharmacies are one of the key points of contact which 
need to undergo change. The overarching aim is to see pharmacists become an integral part of the 
care pathway, contributing to personalised care pathways for patients. The Scottish government state 
WKDW³WKLVZLOOLQYROYHHYHQFORVHUMRLQWZRUNLQJEHWZHHQ*3VSKDUPDFLVWVDQG other community 
VHUYLFHVWREXLOGRQZKDWKDVDOUHDG\EHHQDFKLHYHG´,Q The Right Medicine set the agenda for 
modernising and strengthening the role of pharmacists to deliver improved services to their patients. 
The overall aim would be to see Pharmacists as having a more pronounced role in patient care rather 
than only the prescription of medicines. 
Why do pharmaceutical care pathways need to be more care-focused? Well, the number of over 75s 
will increase by 25% over the next 10 years, thus the pharmaceutical care pathways need to be 
integrated into the NHS and used more effectively. These older people are generally the highest users 
of NHS services and often have complex prescribing needs. The framework of care that was originally 
created to support single-disease morbidities, needs to be revolutionised to provide personalised and 
continuous care which stretches from the local GP to the pharmacies to the hospitals. 
According to the Royal Pharmaceutical Society, 20 years ago, a typical community pharmacist would 
serve up to 500 patients including 150 hypertensives, 50 asthmatics and 20 cancer patients which is 
expected to be much higher now. The ethos to be achieved is that pharmacists these days are 
responsible for the outcome of treatment, not just the supply of medicines. The ideal Pharmaceutical 
FDUHFDQEHGHVFULEHGDVµWKHUHVSRQVLEOHSURYLVLRQRIGUXJWKHUDS\IRUWKHSXUSRVHRIDFKLHYLQJ
GHILQLWHRXWFRPHVWKDWLPSURYHDSDWLHQW¶VTXDOLW\RIOLIHXVLQJDSHUVRQDOLVHGSODQ¶7KLVDSSURDFKLV
particularly useful for managing long term conditions. Therefore, there must be a pharmaceutical 
partnership between the different stakeholders in the health and care industry with the patient at the 
centre of this. 
Scotland have already made significant progress in shifting pharmaceutical care into the community 
and offering more than just prescribing, please refer to figure 1 sourced from the Royal Pharmaceutical 
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Pharmacy Publication (Now or Never: Shaping Pharmacy for the Future). The main elements of the 
current Community Pharmacy contract ± the Chronic Medication Service (CMS), the Minor Ailment 
Service (MAS) and the Public Health Service (PHS) ± have reinforced this approach to pharmaceutical 
care. The CMS, created in 2010, is a service delivering repeat prescriptions for those with long term 
conditions and the MAS, created in 2006, allows the pharmacists to treat people with common 
illnesses. Over 200,000 patients are now registered with CMS with numbers continuing to increase. 
Several GP practices and community pharmacies are engaged in the Early Adopters phase of the 
serial prescribing and dispensing component of the service. 
 
$OLWHUDWXUHUHYLHZFDUULHGRXWE\WKH$OOLDQFHFDOOHGµ7KHSHUFHLYHGUROHRISKDUPDFLVWVDQG
NQRZOHGJHH[SHULHQFHRIVHUYLFHV¶VKHGVOLJKWRQVRPHSHRSOHV¶SHUFHSWLRQVRIFRPPXQLW\
pharmacists. They find that people (who were surveyed) generally see community pharmacists solely 
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as prescribers and for the most part people would rather speak to their GP about important health 
related problems, since the GP has access to their medical record. However, they state that the 
pharmacist can sometimes have more knowledge about the drug interactions and possible side effects 
of drugs than a GP and so confidence in their knowledge is strong. The main downside of the 
FRPPXQLW\SKDUPDF\IRUPRVWLQWHUYLHZHHVLVWKDW\RXGRQ¶WKDYHWKHVDPHUHODWLRQVKLSRUUDSSRUWZLWK
them as you do your GP and so this makes people less likely to approach their pharmacists for medical 
assistance before their GP. With that in mind though, people also said that more awareness of what 
the local pharmacy can offer would make the services more attractive to patients, so being clear on the 
different services you can use through signposting mechanisms would make people more inclined to 
use the community pharmacy before the GP. 
Thanks for reading my blog, I hope I've introduced the pharmaceutical care pathway well for you! My 
next blog post will go on to explore how technology can be implemented to allow for this ideal 
integrated care pathway. 
